Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05699603 · ClinicalTrials.gov registry record · Phase 2
Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients
A Phase 2 study of Actinic Keratosis, sponsored by University of Arizona.
- Active
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 4
- Study locations
NCT05699603 is a Phase 2 study of Actinic Keratosis that is active but no longer recruiting, run by University of Arizona. The registered enrollment target is 56 participants, below the 185-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (70% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05699603, a Phase 2 study of Actinic Keratosis, is active but no longer recruiting, sponsored by University of Arizona.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase IIA study evaluates the effects of calcipotriene plus 5- fluorouracil immunotherapy for skin cancer prevention in organ transplant recipients. Solid organ transplant recipients are at high risk of developing skin cancer. Actinic keratosis (AK), is a premalignant skin lesion that can progress to squamous cell skin cancer. In this study, solid organ transplant recipients with multiple AKs are treated with topical calcipotriene and 5-FU to evaluate how effective this therapy is against AKs and if this could lower their risk of skin cancer. Topical calcipotriene is a form of vitamin D and is used to treat psoriasis. Prior research reported immunomodulatory effects in the skin induced by topical calcipotriene. Topical 5- fluorouracil is a chemotherapy agent and is one of the therapy options for multiple AKs in specific clinical scenarios. Prior research indicates that topical calcipotriene used together with topical 5-FU was more effective in treating multiple AKs than 5-FU alone in individuals with healthy immune system. This study is investigating now if similar beneficial effects can be seen in immunosuppressed individuals who are solid organ transplant recipients.
Conditions Studied
Interventions
- PROCEDURE Biopsy
- DRUG Fluorouracil
- DRUG Calcipotriene
Study Locations (4)
Arizona
- University of Arizona Cancer Center - Prevention Research Clinic - Tucson
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Missouri
- Washington University School of Medicine - St Louis
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2024-07-02 |
| Est. Completion | 2029-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05699603
The ClinicalTrials.gov registry entry for NCT05699603 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 185-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (70% lower). The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Actinic Keratosis appearing as the primary indexed condition, and to 3 interventions - of which Biopsy is the first listed.
NCT05699603 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT05699603 about?
NCT05699603 is a clinical study titled "Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients". This phase IIA study evaluates the effects of calcipotriene plus 5- fluorouracil immunotherapy for skin cancer prevention in organ transplant recipients. Solid organ transplant recipients are at high risk of developing skin cancer. Actinic keratosis (AK), is a premalignant skin lesion that can progr...
What is the current status of trial NCT05699603?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2024-07-02. Estimated completion is 2029-02-01.
What conditions does trial NCT05699603 study?
This clinical trial studies the following conditions: Actinic Keratosis.
What interventions are being tested in trial NCT05699603?
The interventions under investigation include: Biopsy (PROCEDURE), Fluorouracil (DRUG), Calcipotriene (DRUG).
Who is sponsoring clinical trial NCT05699603?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05699603 being conducted?
This trial has 4 study locations across Arizona, Massachusetts, Missouri, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Actinic Keratosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans
RECRUITING · Phase 2
-
The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy
RECRUITING · Phase 1
-
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
ACTIVE NOT RECRUITING · Phase 3
-
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
ACTIVE NOT RECRUITING · Phase 3
-
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
COMPLETED · Phase 3
-
A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.